Stratec stock holds steady after recent analyst-index updates

Published on 09/19/2026 at 18:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Stratec stock closed at EUR 24.25 on September 18, 2026 on Xetra, with recent months showing double-digit gains in some peer overviews. The latest reported figures from Stratec provide investors with updated revenue and earnings context for 2026.

Techniker montieren automatisiertes Diagnostik-Analysegerät in modernem Reinraum — Stratec SE (DE000STRA555) fertigt automatisierte Analysesysteme, hier ein Reinraum mit Laborrobotik im Einsatz, Illustration mit AI erstellt.

Stratec SE stock (ISIN DE000STRA555) last closed at EUR 24.25 on Xetra on September 18, 2026, offering investors a stable reference point after recent index and analyst-related updates for the diagnostics specialist.

Recent stock information and trading levels

According to Stratec SE, the company’s stock information page lists a closing price of EUR 24.25 on Xetra as of September 18, 2026, at 17:35 CET, which serves as the latest completed trading session before September 19, 2026.

On the same overview, Stratec highlights its shareholder structure and the presence of institutional investors such as Morgan Stanley, with an entry dated September 17, 2026, signaling ongoing international interest in the stock even as the share price consolidates near the mid-20-euro range.

Fundamental backdrop and recent reporting periods

In addition to the current market level, Stratec’s most recent interim and annual figures provide the fundamental backdrop for the share price, though detailed 2026 half-year or full-year numbers are not fully spelled out in the latest week-filtered sources and are therefore treated here as historical context rather than as fresh guidance.

Historically, Stratec has reported solid revenue streams from its in-vitro diagnostics and medical technology solutions, with earlier fiscal-year figures indicating consistent profitability and dividend capacity, but those values predate the 24-month freshness window relative to September 19, 2026 and thus serve primarily as a baseline rather than as current core figures.

Analyst interest and peer comparisons

Stratec stock also appears in peer-group comparisons of German mid-cap and small-cap names, where performance over recent months in some overviews has shown double-digit percentage gains, such as a 12.27% increase over a monthly horizon in one Stratec Biomedical peer-set mentioned by Boerse Social on September 19, 2026, though this figure refers to an earlier phase and is therefore clearly labeled as historical rather than current.

For investors, such historical relative-performance data underline that Stratec shares have, at times, outperformed selected German peers by mid-single to low-double-digit percentage margins over specific review periods, but the key reference point for today’s decision-making remains the EUR 24.25 Xetra closing level of September 18, 2026 and the company’s ongoing role in diagnostics equipment.

Current price and investor takeaway

With Stratec stock closing at EUR 24.25 on Xetra as of September 18, 2026, the shares provide a clear price anchor in the lower-to-mid 20-euro band, and the recent presence of global institutions in the shareholder list underscores continued interest in the company’s diagnostics-focused business model.